Your session is about to expire
← Back to Search
PCI-24781 + Temozolomide for Recurrent Brain Cancer
Study Summary
This trial aims to find a better treatment for glioma, a type of brain cancer. It studies the effects of combining PCI-24781 and metronomic temozolomide to see if it can help those whose cancer has returned.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have recovered from side effects of previous cancer treatments.I've had radiation and temozolomide treatment for my cancer.I have recently used specific medications or therapies.I am 19 years old or older.I have a serious heart condition.I have a condition that affects how my body absorbs nutrients.I have a history of HIV, hepatitis, or an ongoing serious infection.I am currently taking valproic acid or another HDAC inhibitor.I am able to care for myself and perform daily activities.I cannot stop taking certain medications before joining the study.My liver is working well.I have been diagnosed with a high-grade brain tumor.I am currently taking certain medications for epilepsy.I am a woman who can have children and my pregnancy test is negative.My kidneys are working well.My blood tests show my bone marrow is working well.I do not have any severe illnesses that could make treatment unsafe for me.It's been over 3 months since my last chemoradiotherapy, or I have signs of my cancer getting worse.I have another active cancer besides the one being studied.
- Group 1: Single arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA given clearance to any single arm trials?
"As Single Arm is in its earliest phase of research, this medication's safety has been rated a 1 due to the limited data available on efficacy and safety."
Is the research team currently seeking new participants for this experiment?
"Affirmative. According to the information hosted on clinicaltrials.gov, this exploratory medical trial is actively searching for 18 participants from one location. The study was first posted on June 26th 2023 and updated most recently on July 10th 2023."
What is the approximate size of the population being treated as part of this investigation?
"Yes, according to clinicaltrials.gov this study is actively enrolling participants with the first post on June 26th 2023 and last update occurring July 10th 20203. The current goal is to secure eighteen patients from one location."
What results are investigators striving to achieve with this medical experiment?
"As the primary outcome, this study aims to ascertain an optimal dosage of PCI-24781 over a 25 month period. Secondary objectives focus on estimating progression-free survival through Kaplan Meier analysis and examining patient quality of life using EORTC QLQ-BN20 scoring system as well as gauging tumor response via RANO Criteria."
Share this study with friends
Copy Link
Messenger